Genetic variant rs117026326 upstream of the general transcription factor II-I (GTF2I) has been associated with primary Sjögren's syndrome, SLE and RA in East Asian populations.
We observed a significant genetic association between the variant rs117026326 and NMOSD (P = 1.09 × 10<sup>-11</sup>, OR = 2.535), however, the association with MS was not significant (P = .4289, OR = 1.129).
Patients carrying genotype TT of rs117026326 had lower 24-hour urinary total protein (24 hours UTP, g/24 hours), 24-hour urinary protein level (g/L·24 hours), lower frequency of the proteinuria and lupus nephritis (LN).
We identified rs117026326 on GTF2I with GWAS significance (P = 1.10 × 10<sup>-15</sup>) and rs13079920 on RBMS3 with suggestive significance (P = 2.90 × 10<sup>-5</sup>) associating with PSS in women.
We identified rs117026326 on GTF2I with GWAS significance (P = 1.10 × 10<sup>-15</sup>) and rs13079920 on RBMS3 with suggestive significance (P = 2.90 × 10<sup>-5</sup>) associating with PSS in women.
We identified rs117026326 on GTF2I with GWAS significance (P = 1.10 × 10<sup>-15</sup>) and rs13079920 on RBMS3 with suggestive significance (P = 2.90 × 10<sup>-5</sup>) associating with PSS in women.
Because of this recent preclinical and clinical identification of a genetic influence on anxiety, we examined whether sequence variation in GTF2I, specifically the single-nucleotide polymorphism rs2527367, interacts with trait and state anxiety to collectively impact neural response to anxiety-laden social stimuli.
Because of this recent preclinical and clinical identification of a genetic influence on anxiety, we examined whether sequence variation in GTF2I, specifically the single-nucleotide polymorphism rs2527367, interacts with trait and state anxiety to collectively impact neural response to anxiety-laden social stimuli.